Antheia

The Department of War's Office of Strategic Capital has signed an $80 million conditional loan commitment with Antheia, Inc., a California-based biotech company that produces plant-derived medicines through fermentation. The deal marks another use of the office's investment authority to fund domestic companies deemed strategically important to national security and supply chain resilience.

Biomanufacturing company Antheia has secured an $80 million conditional funding commitment from the Department of War's Office of Strategic Capital. The investment signals growing federal interest in domestic biomanufacturing capacity, with Antheia working on producing essential medicines through engineered yeast fermentation. The deal ties into broader efforts to strengthen US supply chain security for critical pharmaceutical ingredients.